Literature DB >> 10799657

Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.

T Suuronen1, P Kolehmainen, A Salminen.   

Abstract

L-Deprenyl, an irreversible MAO-B (monoamine oxidase B, EC 1.4.3.4) inhibitor, is used for the treatment of Parkinson's disease and to delay the progression of Alzheimer's disease. L-Deprenyl also exhibits protective effects against neuronal apoptosis which are independent of its ability to inhibit MAO-B. The purpose of this study was to compare the antiapoptotic efficacy of L-deprenyl against different types of apoptotic inducers in three neuronal cell culture models. The level of apoptosis was quantified by measuring the activation of caspase-3 enzyme, which is the main apoptotic executioner in neuronal cells. MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] and LDH (lactate dehydrogenase, EC 1. 1.1.27) assays were used to demonstrate the cytotoxic response of apoptotic treatments. Our results showed that okadaic acid, an inhibitor of protein phosphatase 1 and 2A, induced a prominent increase in caspase-3 activity both in cultured hippocampal and cerebellar granule neurons as well as in Neuro-2a neuroblastoma cells. Interestingly, L-deprenyl offered a significant protection against the apoptotic response induced by okadaic acid in all three neuronal models. The best protection appeared at the concentration level of 10(-9) M. L-Deprenyl also provided a protection against apoptosis after AraC (cytosine beta-D-arabinoside) treatment in hippocampal neurons and Neuro-2a cells and after etoposide treatment in Neuro-2a cells. However, L-deprenyl did not offer any protection against apoptosis caused by serum withdrawal or potassium deprivation. Okadaic acid treatment in vivo is known to induce an Alzheimer's type of hyperphosphorylation of tau protein, formation of beta-amyloid plaques, and a severe memory impairment. Our results show that the okadaic acid model provides a promising tool to study the molecular basis of Alzheimer's disease and to screen the neuroprotective capacity of L-deprenyl derivatives.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799657     DOI: 10.1016/s0006-2952(00)00282-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

Review 2.  Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application.

Authors:  Pradip K Kamat; Shivika Rai; Supriya Swarnkar; Rakesh Shukla; Chandishwar Nath
Journal:  Mol Neurobiol       Date:  2014-04-08       Impact factor: 5.590

3.  Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.

Authors:  Sara A Wahdan; Mariane G Tadros; Amani E Khalifa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-23       Impact factor: 3.000

4.  Neuroprotective and antioxidative effect of cactus polysaccharides in vivo and in vitro.

Authors:  Xianju Huang; Qin Li; Huige Li; Lianjun Guo
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

5.  N-methyl-D-aspartate-stimulated ERK1/2 signaling and the transcriptional up-regulation of plasticity-related genes are developmentally regulated following in vitro neuronal maturation.

Authors:  Xianju Zhou; Changjong Moon; Fei Zheng; Yongneng Luo; Deborah Soellner; Joseph L Nuñez; Hongbing Wang
Journal:  J Neurosci Res       Date:  2009-09       Impact factor: 4.164

6.  Standardized Extract of Bacopa monniera Attenuates Okadaic Acid Induced Memory Dysfunction in Rats: Effect on Nrf2 Pathway.

Authors:  Subhash Dwivedi; Rajasekar Nagarajan; Kashif Hanif; Hefazat Husain Siddiqui; Chandishwar Nath; Rakesh Shukla
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-03       Impact factor: 2.629

7.  Melatonin Reduces GSK3β-Mediated Tau Phosphorylation, Enhances Nrf2 Nuclear Translocation and Anti-Inflammation.

Authors:  Rashmi Das; Abhishek Ankur Balmik; Subashchandrabose Chinnathambi
Journal:  ASN Neuro       Date:  2020 Jan-Dec       Impact factor: 4.146

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.